Welcome to our dedicated page for Spruce Biosciences news (Ticker: SPRB), a resource for investors and traders seeking the latest updates and insights on Spruce Biosciences stock.
Spruce Biosciences reports developments as a late-stage biopharmaceutical company focused on novel therapies for neurological disorders with significant unmet medical need. Its recurring news centers on tralesinidase alfa enzyme replacement therapy, or TA-ERT, for Sanfilippo Syndrome Type B (MPS IIIB), including clinical data presentations, FDA interactions and regulatory planning for the program.
Company updates also cover financial results, capital actions involving common stock and pre-funded warrants, investor conference participation, and additions to commercial leadership as Spruce builds capabilities around a potential rare-disease launch.
Spruce Biosciences (Nasdaq: SPRB) reported Q1 2026 results and TA-ERT program progress for MPS IIIB. Long-term TA-ERT data presented at WORLDSymposium™ showed rapid, durable cerebrospinal fluid heparan sulfate reductions and stabilization of cognitive function and cortical gray matter volume versus natural history.
The company is preparing a planned TA-ERT BLA submission in Q4 2026 and building commercial and development leadership ahead of a potential U.S. launch. Spruce closed a $69.0 million underwritten public offering and secured a term loan facility of up to $50.0 million, extending its cash runway into the second half of 2027. Q1 2026 operating expenses fell to $12.0 million and net loss was $12.3 million, with cash and cash equivalents of $54.1 million on March 31, 2026 and a preliminary $107.3 million on April 30, 2026.
Spruce Biosciences (Nasdaq: SPRB) appointed Brian Walls as Vice President, Market Access and Darren M. Johnson as Vice President, Commercial Operations, supporting a planned commercial launch of tralesinidase alfa (TA-ERT) for Sanfilippo Syndrome Type B (MPS IIIB) targeted next year. Each executive will receive 3,500 RSUs vesting annually over four years under an inducement plan filed on Form S-8.
The hires bring extensive rare-disease launch experience and are intended to build market access, pricing, analytics, and launch infrastructure ahead of potential approval.
Spruce Biosciences (Nasdaq: SPRB) priced an underwritten public offering of 1,150,000 common shares at $50.00 per share and pre-funded warrants to purchase 50,000 shares at $49.99 per warrant, producing expected gross proceeds of $60 million.
The offering is expected to close on April 22, 2026, subject to customary closing conditions, and underwriters hold a 30-day option for up to 180,000 additional shares.
Spruce Biosciences (NASDAQ: SPRB) commenced an underwritten public offering of common stock or pre-funded warrants on April 20, 2026. The offering includes a 30-day underwriter option to purchase up to 15% additional shares. The offering is subject to market conditions and final prospectus terms.
Joint book-runners are Leerink Partners, Guggenheim Securities, and Oppenheimer; Jones and Craig-Hallum are co-managers. Securities are offered under a Form S-3 shelf registration declared effective on November 26, 2025. No assurance as to completion, size, or terms.
Spruce Biosciences (Nasdaq: SPRB) reported full-year 2025 results and corporate updates on March 9, 2026. Key items: the company completed positive Type B FDA meetings, anticipates a BLA submission for TA-ERT in Q4 2026, appointed a chief commercial officer, and secured a loan facility up to $50.0 million with $15.0 million funded.
Financials: cash and equivalents were $48.9M at year-end, R&D expenses declined to $19.5M, total operating expenses were $36.5M, and net loss was $39.0M for 2025.
Spruce Biosciences (Nasdaq: SPRB) appointed Dale Hooks as Chief Commercial Officer on March 9, 2026. Mr. Hooks brings nearly 35 years of commercial experience and leadership on 21 new product launches. Spruce said he will support preparation for a planned BLA submission for tralesinidase alfa (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB). The company granted Mr. Hooks 11,000 restricted stock units as an inducement award, subject to four-year time-based vesting in equal annual installments.
Spruce Biosciences (Nasdaq: SPRB) said CEO Javier Szwarcberg will present at two investor conferences in Miami in March 2026: the Leerink Global Healthcare Conference on March 9, 2026 at 11:20 a.m. ET and The Citizens Life Sciences Conference on March 10, 2026 at 12:30 p.m. ET.
Both presentations will be fireside chats with 1x1 meetings; live webcasts will be available on the company website and archived for approximately 90 days.
Spruce Biosciences (Nasdaq: SPRB) completed two Type B meetings with the U.S. FDA and will pursue a BLA for tralesinidase alfa enzyme replacement therapy (TA-ERT) for Sanfilippo syndrome type B (MPS IIIB).
The FDA indicated CSF HS-NRE could serve as a reasonably likely surrogate endpoint for accelerated approval and requires one DP PPQ batch at submission plus a second DP PPQ batch before midcycle review, shifting the anticipated BLA submission to Q4 2026.
Spruce Biosciences (Nasdaq: SPRB) said CEO Javier Szwarcberg will join a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026 at 3:20 p.m. ET. The session will be webcast live, with an archived replay available on the company's events page for about 90 days.
Spruce Biosciences (Nasdaq: SPRB) reported long-term data showing weekly tralesinidase alfa enzyme replacement therapy (TA-ERT) normalized CSF HS-NRE and stabilized cognitive, communication, and motor outcomes over up to six years versus untreated natural history patients. Approximately 6,000 doses were administered to 22 patients with a safety profile consistent with intracerebroventricular administration. A sibling case comparison showed higher functioning in a treated sibling versus an untreated sibling at similar ages. The company said it will pursue a biologics license application and potential U.S. FDA approval.